Adimadhyam S, et al. - Using data from the Truven Health MarketScan (2009-2015) databases, an active comparator, new user cohort study was conducted to assess the risk of amputations correlated with sodium-glucose co-transporter-2 inhibitor (SGLT2i) vs dipeptidyl peptidase-4 inhibitors (DPP4i). Patients aged ≥ 18 years newly initiating SGLT2i or DPP4i between April 1, 2013 and March 31, 2015 were involved. Researchers used Cox proportional hazards models to estimate hazard ratios (HR) and robust 95% confidence intervals (CI) for amputation risk. Though not statistically significant, all SGLT2i had an elevated risk for amputations.